Case Study:
Finding Ultra Rare Disease Patients with AI Using Claims and EHR Data
Ultra Rare Disease Patient Identification Using AI with Claims and EHR Data
Ultra rare disease patients are notoriously difficult to find due to the fact that they are ultra rare.
The Client Problem
Finding patients with a specific ultra rare disease was difficult for the client. They did all the usual approaches of educating every physician who may come into contact with a patient of this type but this was costing significantly and yielding little return.
The Solution
The team turned to Eularis for Artificial Intelligence Powered Analytics to help. We were given access to claims databases that the client had purchased. We began by identifying the patient journey of the few patients who had been diagnosed, and from that, we were able to understand the specifics of the tests and medical journey of those patients. We then also accessed EHR data that we have the ability to source from over 30 countries and used that to then identify other patients with similar early-stage symptoms with a high probability of having the condition.
The Outcome
29 previously undiagnosed patients were able to get confirmed diagnoses and appropriate treatment early in their disease progression which led to an improved clinical outcome for them and a significant financial return for the client. Considered the ultra-rare condition, this was an extremely high number of additional patients resulting in hundreds of millions of additional revenue for the lifetime of these patients.
To achieve these kinds of results, contact Eularis today.
Latest Blogs
Check out our latest blogs
Are LLMs Already On Their Way to Being Obsolete?
The AI world is racing forward with near-religious confidence in large language models, yet one of the field’s most influential pioneers is already drafting their
CRO 2.0: Transforming Tomorrow’s Clinical Research Process with Artificial Intelligence
The clinical trial ecosystem – a $90 billion engine driving medical innovation is struggling under the burden of its own complexity. Despite significant advancements in
The Hidden Cost of Having No AI Strategy (Spoiler: It’s Not What You Think)
In the past few years, almost 70% of biopharma companies have initiated AI initiatives. Yet, fewer than 20% report a cohesive AI strategy at the